Literature DB >> 24411606

Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer.

Pirus Ghadjar1, Michael J Zelefsky1, Daniel E Spratt1, Per Munck af Rosenschöld2, Jung Hun Oh2, Margie Hunt2, Marisa Kollmeier1, Laura Happersett2, Ellen Yorke2, Joseph O Deasy2, Andrew Jackson3.   

Abstract

PURPOSE: To determine the potential association between genitourinary (GU) toxicity and planning dose-volume parameters for GU pelvic structures after high-dose intensity modulated radiation therapy in localized prostate cancer patients. METHODS AND MATERIALS: A total of 268 patients who underwent intensity modulated radiation therapy to a prescribed dose of 86.4 Gy in 48 fractions during June 2004-December 2008 were evaluated with the International Prostate Symptom Score (IPSS) questionnaire. Dose-volume histograms of the whole bladder, bladder wall, urethra, and bladder trigone were analyzed. The primary endpoint for GU toxicity was an IPSS sum increase ≥10 points over baseline. Univariate and multivariate analyses were done by the Kaplan-Meier method and Cox proportional hazard models, respectively.
RESULTS: Median follow-up was 5 years (range, 3-7.7 years). Thirty-nine patients experienced an IPSS sum increase ≥10 during follow-up; 84% remained event free at 5 years. After univariate analysis, lower baseline IPSS sum (P=.006), the V90 of the trigone (P=.006), and the maximal dose to the trigone (P=.003) were significantly associated with an IPSS sum increase ≥10. After multivariate analysis, lower baseline IPSS sum (P=.009) and increased maximal dose to the trigone (P=.005) remained significantly associated. Seventy-two patients had both a lower baseline IPSS sum and a higher maximal dose to the trigone and were defined as high risk, and 68 patients had both a higher baseline IPSS sum and a lower maximal dose to the trigone and were defined as low risk for development of an IPSS sum increase ≥10. Twenty-one of 72 high-risk patients (29%) and 5 of 68 low-risk patients (7%) experienced an IPSS sum increase ≥10 (P=.001; odds ratio 5.19).
CONCLUSIONS: The application of hot spots to the bladder trigone was significantly associated with relevant changes in IPSS during follow-up. Reduction of radiation dose to the lower bladder and specifically the bladder trigone seems to be associated with a reduction in late GU toxicity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24411606      PMCID: PMC4581453          DOI: 10.1016/j.ijrobp.2013.10.042

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

Review 1.  The relationship between external beam radiotherapy dose and chronic urinary dysfunction--a methodological critique.

Authors:  Tara Rosewall; Charles Catton; Geoffrey Currie; Andrew Bayley; Peter Chung; Janelle Wheat; Michael Milosevic
Journal:  Radiother Oncol       Date:  2010-10       Impact factor: 6.280

Review 2.  Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature.

Authors:  Lars Budäus; Michel Bolla; Alberto Bossi; Cesare Cozzarini; Juanita Crook; Anders Widmark; Thomas Wiegel
Journal:  Eur Urol       Date:  2011-10-06       Impact factor: 20.096

Review 3.  Radiation dose-volume effects of the urinary bladder.

Authors:  Akila N Viswanathan; Ellen D Yorke; Lawrence B Marks; Patricia J Eifel; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

4.  Characteristics of spontaneous activity in the bladder trigone.

Authors:  Alexander Roosen; Changhao Wu; Guiping Sui; Rasheda A Chowdhury; Pravina M Patel; Christopher H Fry
Journal:  Eur Urol       Date:  2008-06-20       Impact factor: 20.096

Review 5.  The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy.

Authors:  L B Marks; P R Carroll; T C Dugan; M S Anscher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

6.  Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics.

Authors:  Wilma D Heemsbergen; Abrahim Al-Mamgani; Marnix G Witte; Marcel van Herk; Floris J Pos; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-07       Impact factor: 7.038

7.  Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.

Authors:  Asif Harsolia; Carlos Vargas; Di Yan; Donald Brabbins; David Lockman; Jian Liang; Gary Gustafson; Frank Vicini; Alvaro Martinez; Larry L Kestin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

8.  Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

Authors:  Michael J Zelefsky; Marisa Kollmeier; Brett Cox; Anthony Fidaleo; Dahlia Sperling; Xin Pei; Brett Carver; Jonathan Coleman; Michael Lovelock; Margie Hunt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

9.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Authors:  Michael J Zelefsky; Emily J Levin; Margie Hunt; Yoshiya Yamada; Alison M Shippy; Andrew Jackson; Howard I Amols
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-15       Impact factor: 7.038

10.  Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

Authors:  M J Barry; W O Williford; Y Chang; M Machi; K M Jones; E Walker-Corkery; H Lepor
Journal:  J Urol       Date:  1995-11       Impact factor: 7.450

View more
  36 in total

1.  Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.

Authors:  Tomasz Barelkowski; Peter Wust; David Kaul; Sebastian Zschaeck; Waldemar Wlodarczyk; Volker Budach; Pirus Ghadjar; Marcus Beck
Journal:  Strahlenther Onkol       Date:  2019-12-23       Impact factor: 3.621

2.  Dosimetric and volumetric effects in clinical target volume and organs at risk during postprostatectomy radiotherapy.

Authors:  Ahmed Gawish; Ahmed Ali Chughtai; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2018-10-17       Impact factor: 3.621

3.  Tensor Regression-based Model to Investigate Heterogeneous Spatial Radiosensitivity After I-125 Seed Implantation for Prostate Cancer.

Authors:  Kazuma Kobayashi; Naoya Murakami; Kana Takahashi; Koji Inaba; Hiroshi Igaki; Ryuji Hamamoto; Jun Itami
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

4.  Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.

Authors:  Thomas P Kole; Michael Tong; Binbin Wu; Siyuan Lei; Olusola Obayomi-Davies; Leonard N Chen; Simeng Suy; Anatoly Dritschilo; Ellen Yorke; Sean P Collins
Journal:  Acta Oncol       Date:  2015-05-14       Impact factor: 4.089

5.  Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy.

Authors:  Maria Thor; Caroline Olsson; Jung Hun Oh; Stine Elleberg Petersen; David Alsadius; Lise Bentzen; Niclas Pettersson; Ludvig Paul Muren; Morten Høyer; Gunnar Steineck; Joseph O Deasy
Journal:  Radiother Oncol       Date:  2016-02-12       Impact factor: 6.280

6.  Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy.

Authors:  Sangkyu Lee; Sarah Kerns; Harry Ostrer; Barry Rosenstein; Joseph O Deasy; Jung Hun Oh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-31       Impact factor: 7.038

7.  Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.

Authors:  A Zapatero; M Roch; D Büchser; P Castro; L Fernández-Banda; G Pozo; O Liñán; C Martin de Vidales; A Cruz-Conde; F García-Vicente
Journal:  Clin Transl Oncol       Date:  2017-04-03       Impact factor: 3.405

8.  Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.

Authors:  Maria Thor; Joseph O Deasy; Rebecca Paulus; W Robert Lee; Mahul B Amin; Deborah W Bruner; Daniel A Low; Amit B Shah; Shawn C Malone; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; Elizabeth M Gore; Michele Albert; Thomas M Pisansky; Sergio L Faria; Yuhchyau Chen; Bridget F Koontz; Gregory P Swanson; Stephanie L Pugh; Howard M Sandler
Journal:  Radiother Oncol       Date:  2019-03-05       Impact factor: 6.280

9.  Prostate cancer treated with image-guided helical TomoTherapy® and image-guided LINAC-IMRT : Correlation between high-dose bladder volume, margin reduction, and genitourinary toxicity.

Authors:  Sonia Drozdz; Michael Schwedas; Henning Salz; Susan Foller; Thomas G Wendt
Journal:  Strahlenther Onkol       Date:  2016-01-07       Impact factor: 3.621

10.  Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.

Authors:  Lara Hathout; Michael R Folkert; Marisa A Kollmeier; Yoshiya Yamada; Gil'ad N Cohen; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.